-59.8%
MSTR vs MRNA
+485.7%
-545.5%
-77.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.9% | +5.4% | -3.5% | +1.4% |
| 7D | -8.3% | -1.1% | -7.2% | -8.2% |
| 30D | +38.1% | +126.1% | -88.0% | +17.7% |
| 3M | +9.0% | +190.0% | -181.0% | -14.4% |
| 6M | -5.3% | +157.2% | -162.5% | -23.5% |
| YTD | -13.8% | +388.2% | -402.0% | -39.6% |
| 1Y | -59.8% | +467.0% | -526.9% | -72.3% |
| All | -59.8% | +485.7% | -545.5% | -72.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling